To evaluate the effectiveness of a deintensified 60-Gy radiotherapy regimen in patients with HPV-associated oropharyngeal carcinoma, focusing on patient outcomes.
Key Findings:
5-year locoregional recurrence rate was 3.4% (95% CI, 1.1%–5.8%).
Progression-free survival was 86.5% (95% CI, 82.1%–91.0%), and overall survival was 92.4% (95% CI, 89.0%–96.0%).
Distant recurrence occurred in 7.3% of patients at 5 years.
Among lower-risk patients treated with radiotherapy alone, 5-year progression-free survival was 93.8%.
Interpretation:
The study suggests that modest dose deintensification of 60-Gy radiotherapy can achieve high rates of locoregional control in selected patients with HPV-associated oropharyngeal carcinoma, indicating potential for future research.
Limitations:
Single-arm design without a standard-dose comparator group, which may affect the robustness of the findings.
Treatment delivery within a specialized academic system may limit generalizability to broader cooperative-group practice settings.
Long-term toxicity and quality-of-life outcomes were not fully evaluated, which is crucial for comprehensive understanding.
Conclusion:
Findings support ongoing discussions about deintensification in HPV-associated OPC but do not change the current standard of care; further studies are needed.
